EP2707697A1 - Procédé et dispositif de dosage pour déterminer le taux d'acide urique et de créatinine - Google Patents

Procédé et dispositif de dosage pour déterminer le taux d'acide urique et de créatinine

Info

Publication number
EP2707697A1
EP2707697A1 EP12714642.1A EP12714642A EP2707697A1 EP 2707697 A1 EP2707697 A1 EP 2707697A1 EP 12714642 A EP12714642 A EP 12714642A EP 2707697 A1 EP2707697 A1 EP 2707697A1
Authority
EP
European Patent Office
Prior art keywords
wavelength
uric acid
spectral absorption
liquid
creatinine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12714642.1A
Other languages
German (de)
English (en)
Inventor
Aleksei Talisainen
Indrek NEIVELT
Georgy KONOPLEV
Alexander Frorip
Christoph Nacke
Alexander Vasilevsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ldiamon AS
Original Assignee
Ldiamon AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ldiamon AS filed Critical Ldiamon AS
Publication of EP2707697A1 publication Critical patent/EP2707697A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/20—Measuring for diagnostic purposes; Identification of persons for measuring urological functions restricted to the evaluation of the urinary system
    • A61B5/201—Assessing renal or kidney functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1601—Control or regulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1601—Control or regulation
    • A61M1/1603—Regulation parameters
    • A61M1/1605—Physical characteristics of the dialysate fluid
    • A61M1/1609—Physical characteristics of the dialysate fluid after use, i.e. downstream of dialyser
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0496—Urine
    • A61M2202/0498—Urea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/15—Detection of leaks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3306—Optical measuring means
    • A61M2205/3313—Optical measuring means used specific wavelengths
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
    • G01N2021/3181—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths using LEDs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2201/00—Features of devices classified in G01N21/00
    • G01N2201/06—Illumination; Optics
    • G01N2201/062—LED's
    • G01N2201/0627—Use of several LED's for spectral resolution

Definitions

  • the invention relates to a method for photometric determination of the uric acid and Kreatiningehaits a liquid, in particular in a dialysate as a control variable of a Härnodialyse harmony. Furthermore, it relates to a corresponding
  • Spectrophotometric methods for the quantitative determination of ingredients in compounds or cloth like substances have long been known and especially in use for the analysis of the composition of body fluids or in contact with a living body brought fluids in medical laboratory use.
  • Dialysis fluid discharged, consumed dialysis fluid measured and used as a measure of the treatment success.
  • this requires a sampling and laboratory evaluation and is therefore hardly “online" during the
  • Dialysis fluid can be effected. In this method, however, practical problems have occurred in the calibration of the sensors and the compensation of a (occasionally differing) basic conductivity.
  • Markersubstanzen in liquids - such as in Diaiyseirrikeit - are provided.
  • a corresponding blood detector is used in dialysis systems, in particular for rapid detection of patient-critical conditions as a result of malfunction of the arrangement (such as a membrane rupture of the membrane filter, the interchanging of terminals or hemolysis).
  • the latter document also contains a number of references for further prior art.
  • DIAMON dialysis adequacy factor
  • Uric acid concentration can be used in Diaiysat.
  • the method itself and its modifications are based on the measurement of spectral transmission of the dialyzate in the UV range, e.g. in the range of 270 - 330 nm, in one of the expiration of the
  • Dialysis apparatus arranged flow cell and an application of the Savitzky-Golay algorithm for the determination of uric acid concentration.
  • Object of the present invention is to provide a further improved detection method and a corresponding detection device, which in particular provide more accurate results and to enable more reliable statements.
  • One aspect of the invention is that in the liquid ultraviolet radiation at three wavelengths in the wavelength range between 235 nm and 300 nm irradiated and the radiation absorption in the liquid at the predetermined wavelengths is measured, of which a first in a first subregion between 235 nm and 250 nm, a second in a second subregion between 255 nm and 270 nm and a third in a third subregion between 280 nm and 295 nm.
  • the first wavelength is 240-245 nm
  • the second wavelength 260-265 nm is a third wavelength 285-290 nm.
  • the UV radiation is irradiated discretely at the predetermined wavelengths
  • the analytically relevant wavelengths may be filtered out of a continuous or band spectrum of another type of radiation generator and selectively radiated into the sample, or a broadband absorption signal may be appropriately filtered prior to reaching the detector.
  • the processing of the measurement results is an input of the respective specific spectral
  • 2nd order includes. If simplified assumptions can be made with regard to the 2nd order, the signal processing can be limited to the 1st order; For details, see below.
  • the above-mentioned further ingredient is also to be understood as meaning a mixture of a plurality of chemical compounds, which may in particular include at least one product of the nucleic acid metabolism and which to a certain extent produce a metrological "background" of the spectroscopic analysis.
  • Hemodialysis treatment performed several measurements and calculations at predetermined times or at predetermined intervals and each
  • a gradient curve is formed from the calculated concentration values, from which a control signal is derived.
  • a corresponding progression curve is well suited for an accompanying graphical representation to facilitate medical monitoring and allows the consideration of different assumptions about measurement errors, the course of treatment, etc. in the control of treatment due to the
  • the proposed detection device comprises
  • a UV radiation source directed to the transmission cuvette for providing radiation at three predetermined wavelengths, particularly in the o.g. Subregions of the UV spectrum are,
  • a signal processing device for processing the photodetector signals and for calculating the content of the relevant components in the liquid.
  • the UV radiation source has a first LED emitting at the first wavelength, in particular at 240-245 nm, and a second LED emitting at the second wavelength, in particular at 260-265 nm, and a third , at the third wavelength, especially at 285-290 nm,
  • a broadband UV radiation source with a filter for filtering out the required wavelengths either on the irradiation side or on the detection side.
  • the detection device is a continuation of a dialysis system
  • the transmission cuvette is a measuring cuvette or a section of a fluid line through which spent dialysis fluid discharged from the dialysis system flows. Especially here is the
  • Signal processing device of the detection device connected to an input of a control device of the dialysis device such that the operation of the dialysis device is controllable due to the detected with the detection device control variable.
  • FIG. 1 is a schematic overall view of a dialysis device with a detection device according to the invention, Fig. 2 and 3 spectral absorption curves to illustrate
  • the device for measurement of uric acid concentration in the dialyzate during a dialysis comprises a light source module 1 with three (not separately shown) light sources with emission wavelengths of 242 nm, 263 nm and 287 nm; a light source power supply 2; an optic 3 for beam forming; a quartz flow cell 4, light sensors 5 for recording the LED radiation passing through the cuvette; a recording and processing module 6 for electrical signals including AD / converters and amplifiers; a data acquisition and processing module 7; a computer connection module 8 and a computer 9 with installed special software.
  • This detection device is in a light source module 1 with three (not separately shown) light sources with emission wavelengths of 242 nm, 263 nm and 287 nm; a light source power supply 2; an optic 3 for beam forming; a quartz flow cell 4, light sensors 5 for recording the LED radiation passing through the cuvette; a recording and processing module 6 for electrical signals including AD / converters and amplifiers; a data acquisition and processing module 7; a
  • Dialysis assembly 10 integrated, which includes an extracorporeal blood circulation 11, a dialyzer 12 and a Diaiysataufleungsmodul 13.
  • the operating principle of the arrangement shown in FIG. 1 is as follows: The light from the light source module 1 is directed with the aid of the beam shaping optics 3 to the working area of the quartz transmission line 4 connected to the outflow tube of the dialysis apparatus, and the transmitted light is focused on the light sensors 5 , Using the recording mode 6, electrical signals output from each light sensor are amplified and digitized.
  • Data processing module 7 is for setting the recording mode in the module 6, the reference signal recording, determination of
  • the device allows automated measurement of the dialysate transmission coefficient in the course of the dialyzer at wavelengths of 242 nm, 263 nm and 287 nm at precisely defined times, a calculation of the concentration of uric acid, creatinine and an unknown component, taking into account the individual spectral absorption characteristics of the patient , a compilation of diagrams of the time / concentration and the amount of uric acid and creatinine withdrawn from the patient's body during the treatment, one Display the results on a computer screen and save them in a database.
  • Dialysis machine is connected, the extracorporeal circuit 11 and the dialyzer 12 are filled with Diaiysef spasstechnik. At this time flows from the
  • Dialysate preparation module 13 through the drain hose of the dialysis machine 10 clean dialysate, which contains no measured during monitoring substances and is used as a reference. At this time, the
  • Transmission coefficient is determined by the data acquisition and
  • Data processing module calculated for each channel (at 242 nm, 263 nm and 287 nm). The received data is buffered and transmitted to the computer 9 on demand by the computer connection module 8.
  • the settings of the monitoring mode (duration, measuring interval) and
  • Creatinine and, if necessary, further material balances via time diagrams and the saving of the results are carried out by the special software that runs on the computer 9.
  • the calculation of the concentration of the investigated components is carried out under
  • the proposed method is based on the Beer-Lambert law and the
  • the spectral absorption of uric acid at the wavelengths 7, lf ⁇ 2 , ⁇ 3 , k 2 (ii k 2 (li) k Hm is in each case the spectral absorption of the second constituent at the wavelengths ⁇ 2 , ⁇ 3 , s lw , s xv e l ⁇ i) the specific spectral
  • Absorption index for uric acid at the wavelengths ⁇ ⁇ , ⁇ 2 , ⁇ 3 is 7 ⁇ 2 ⁇ ) ⁇ ⁇ 1 ⁇ )> ⁇ ⁇ > ⁇ the specific spectral absorption index for the second component at the wavelengths ⁇ , ⁇ 2 , ⁇ 3 is the specific spectral
  • Second order absorption coefficient for uric acid at wavelengths XX 2 , ⁇ 3 ' st ' e 2 ⁇ ], ) ' & 2 2 )' & 2, ) is the second order spectral absorption coefficient for the second constituent at wavelengths it ⁇ 2 , ⁇ 3 is, C ⁇ the
  • Urea concentration in the dialysate, and C 2 is the urea concentration of the second component in the dialysate.
  • the concentration of the components is derived by solving the simultaneous equation (1) for Ci, C 2 and C 3 .
  • the substances that make a major contribution to the spectral absorption of dialysate in the UV range are low molecular weight components such as Uric acid, creatinine, phosphates, low molecular weight proteins (albumines) and the like; etc .; specifically, uric acid and creatinine and a third ingredient.
  • ⁇ ⁇ is the specific absorption coefficient of the first order and ⁇ 'is the specific absorption coefficient of the second order.
  • the sign of the second term defines the nature of the dependence of the absorption coefficient on the concentration.
  • spectral range of 200-300 nm In the spectral range of 200-300 nm, a close ratio (p> 0.9) between the spectral dialysate absorption and the concentration of potential low-uremic urinary toxins (urea, creatinine and uric acid) removed from the body is observed. Differentiation of the spectral absorbance spectra of the dialysate in the range of 235-300 nm can be estimated by the ratio of absorbance values in sub-ranges ranging from 235-250 nm, 255-270 nm and 280-300 nm.
  • the individuality of the spectral dialysate absorption in the range of 235-300 nm which is described by a ratio of integer absorption values in the ranges 235-250 nm, 255-270 nm and 280-300 nm, can be determined by the
  • concentrations of the components in the dihydrate are calculated by measuring the light transmission at three wavelengths, each settling in one of the spectral regions responsible for spectrum individuality.
  • the absorption coefficient ⁇ for each constituent must be calculated at the selected wavelengths.
  • Absorption spectra of the solutions can be measured with known concentration, wherein spectral properties of the second component can be estimated only indirectly by correlating differently shaped dialysate absorption spectra and then modeled.
  • Figs. 2 to 4 serve to illustrate the above-mentioned
  • FIG. 2 shows the specific spectral absorption coefficients of the 1st order (solid line) and 2nd order (dashed line) of uric acid in FIG. 2
  • FIG. 3 shows the specific spectral absorption coefficients of creatinine recorded and shown in the same way.
  • Fig. 4 shows the spectral absorption curves recorded in a dialysate during hemodialysis at 15, 30, 60 and 150 minutes in one embodiment of the proposed method, again using a cuvette with an optical thickness of 5 mm and distilled water as a reference.
  • the proposed method uses a cuvette with an optical thickness of 5 mm and distilled water as a reference.
  • Uric acid concentrations of 0.092 mmol / L and creatinine of 0.210 mmol / L and 150 minutes of diaiysis duration were 0.041 mmol / L and 0.109 mmol / L, respectively.
  • the application of the aforementioned method makes it possible to carry out a calculation of the uric acid concentration in the dialysate by measuring transmission coefficients at two wavelengths with an accuracy of ⁇ 10%.
  • flow cells allows a uric acid concentration calculation using the proposed method in on-line operation during treatment and a creation of a time chart of the
  • the proposed method can be used to calculate the total amount of uric acid removed during the dialysis session.

Landscapes

  • Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Physiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

L'invention concerne un procédé de détermination photométrique des teneurs en acide urique et en créatinine d'un liquide, en particulier d'un dialysat, en tant que grandeurs de pilotage d'un traitement par hémodialyse. On fait passer dans le liquide un rayonnement UV à trois longueurs d'onde dans la plage allant de 235 nm à 300 nm, et on mesure l'absorption du rayonnement dans le liquide aux longueurs d'onde prédéfinies, dont une première dans la plage partielle allant de 235 nm à 250 nm, une deuxième dans une deuxième plage partielle allant de 255 nm à 270 nm, et une troisième dans une troisième plage partielle allant de 280 nm à 300 nm. A partir des résultats de mesure, on calcule les taux d'acide urique et de créatinine ainsi que, facultativement, le taux d'un troisième constituant.
EP12714642.1A 2011-05-11 2012-04-04 Procédé et dispositif de dosage pour déterminer le taux d'acide urique et de créatinine Withdrawn EP2707697A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011101193A DE102011101193A1 (de) 2011-05-11 2011-05-11 Verfahren und Nachweisvorrichtung zur Bestimmung des Harnsäure- und Kreatinin-Gehalts
PCT/EP2012/056190 WO2012152514A1 (fr) 2011-05-11 2012-04-04 Procédé et dispositif de dosage pour déterminer le taux d'acide urique et de créatinine

Publications (1)

Publication Number Publication Date
EP2707697A1 true EP2707697A1 (fr) 2014-03-19

Family

ID=45974296

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12714642.1A Withdrawn EP2707697A1 (fr) 2011-05-11 2012-04-04 Procédé et dispositif de dosage pour déterminer le taux d'acide urique et de créatinine

Country Status (3)

Country Link
EP (1) EP2707697A1 (fr)
DE (1) DE102011101193A1 (fr)
WO (1) WO2012152514A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012112790A1 (de) * 2012-12-20 2014-06-26 B. Braun Avitum Ag Verfahren und Vorrichtung zur Bestimmung von Abfallprodukten wie Indoxyl Sulfate in der Dialyse
DE102014106489A1 (de) 2014-05-08 2015-11-12 B. Braun Avitum Ag Vorrichtung und Vorrichtungs-Steuerungsverfahren zur quantitativen Konzentrationsbestimmung ausgewählter aus einem Patientenkörper ausgefilterter Substanzen in einer Flüssigkeit
CN106896082B (zh) * 2017-04-26 2024-02-13 上海健康医学院 一种血透血液中尿素氮肌酐含量在线监测方法及系统
CN106918573B (zh) * 2017-04-26 2023-06-13 上海健康医学院 一种血透透析液中肌酐含量在线监测方法及系统
CN110411969B (zh) * 2019-08-02 2021-10-01 淮阴师范学院 紫外分光光度法测定禽类粪便中尿酸含量的方法
CN112525845A (zh) * 2020-11-12 2021-03-19 德莱福(重庆)医疗器械有限公司 同时测试透析器清除率模拟液中肌酐和vb12浓度的双波长紫外分光光度法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772606A (en) * 1994-03-04 1998-06-30 Kyoto Dai-Ichi Kagaku Co., Ltd. Method of and apparatus for measuring uric components
SE525639C2 (sv) 1998-06-04 2005-03-22 Thore Falkvall Bestämning av slaggprodukter i dialysvätska med hjälp av optisk sensor
DE102006029899B4 (de) 2006-06-29 2009-06-04 Fresenius Medical Care Deutschland Gmbh Spektroskopischer Detektor und Verfahren zur Bestimmung von Blut und biologischen Markersubstanzen in Flüssigkeiten
WO2009071102A1 (fr) 2007-12-04 2009-06-11 Tallinn University Of Technology Procédé et dispositif optique pour mesurer des concentrations de substances dans des fluides biologiques
EP2577270A1 (fr) 2010-05-27 2013-04-10 Tallinn University Of Technology Procédé et dispositif de mesure et de surveillance des concentrations de substances dans un liquide biologique
DE102010034626A1 (de) * 2010-08-17 2012-02-23 B. Braun Avitum Ag Vorrichtung zur extrakorporalen Blutbehandlung

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JANA JEROTSKAJA ET AL: "Optical dialysis adequacy sensor: wavelength dependence of the ultra violet absorbance in the spent dialysate to the removed solutes", THE EFFECT OF APPLIED COMPRESSIVE LOADING ON TISSUE-ENGINEERED CARTILAGE CONSTRUCTS CULTURED WITH TGF-BETA3., 1 August 2007 (2007-08-01), pages 2960 - 2963, XP055326569, ISSN: 1557-170X, DOI: 10.1109/IEMBS.2007.4352950 *
See also references of WO2012152514A1 *

Also Published As

Publication number Publication date
WO2012152514A1 (fr) 2012-11-15
DE102011101193A1 (de) 2012-11-15

Similar Documents

Publication Publication Date Title
EP2942614B1 (fr) Dispositif et procédé de commande de dispositif destiné à la détermination de concentration quantitative de substances sélectionnées dans un liquide extraites par filtration d'un corps d'un patient
DE69916053T2 (de) Verfahren und bestimmung von abfallprodukten in dialyseflüssigkeiten während dialysebehandlungen
DE102010034626A1 (de) Vorrichtung zur extrakorporalen Blutbehandlung
DE102006029899B4 (de) Spektroskopischer Detektor und Verfahren zur Bestimmung von Blut und biologischen Markersubstanzen in Flüssigkeiten
EP2579910B1 (fr) Dispositif de traitement sanguin extracorporel doté d'un dispositif de mesure pour déterminer la luminescence du liquide de dialyse usagé
DE102006036920B3 (de) Verfahren zur Messung der Glukosekonzentration in pulsierendem Blut
EP2707697A1 (fr) Procédé et dispositif de dosage pour déterminer le taux d'acide urique et de créatinine
EP2799097B1 (fr) Dispositif destiné au traitement extracorporel du sang
EP2710348B1 (fr) Procédé et système de détermination de la concentration de substances dans des liquides corporels
EP2579911B1 (fr) Ensemble de dialyse avec dispositif de détection
DE102009017304A1 (de) Vorrichtung und Verfahren zur Messung eines Blutbestandteils im Blut für eine extrakorporale Blutbehandlungsvorrichtung
EP3431118A1 (fr) Dispositif et procédé de mise en uvre d'une dialyse isonatramique
EP3063541B1 (fr) Procédé et dispositif de détection d'hémolyse ou de détermination d'un facteur de correction corrigeant l'influence de l'hémolyse sur une mesure de l'hématocrite
DE102011008482A1 (de) UV-Detektoranordnung
EP2590562B1 (fr) Détermination de la concentration d'un constituant du sang dans une conduite flexible
EP2397167A1 (fr) Dispositif destiné au traitement du sang extracorporel comprenant un dispositif de mesure pour la détermination d'un paramètre de luminescence de dialysat usé
EP3017292B1 (fr) Dispositif et procédé de détermination de la concentration d'une substance dans un contenant flexible
DE102009005402B4 (de) Verfahren zum Bestimmen der Konzentration von Blutbestandteilen in einer mit Blut gefüllten Schlauchleitung
EP0679064A1 (fr) Procede et dispositif de determination percutanee non invasive de la concentration de substances presentes dans des liquides ou des tissus du corps humain
EP2746771B1 (fr) Dispositif de détermination de déchets tels que l'indoxyl sulfate dans la dialyse
DE102017008631A1 (de) Anordnung zur Filterung von Blut, insbesondere im Rahmen einer extrakorporalen Leberersatztherapie, sowie Verfahren zum Betrieb serselben
DE202010017537U1 (de) Nachweisvorrichtung zur Bestimmung des Urea-Gehalts
DE102011012674B3 (de) Verfahren und Nachweisvorrichtung zur Bestimmung eines Nierenfunktionsparameters
EP4132604B1 (fr) Capteur optique pour déterminer une dose de dialyse
EP3171154A1 (fr) Procédé d'étalonnage d'un signal de mesure et destiné à asservir une dimension quantitative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131010

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20161215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170426